Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368322 | 0.92 | PDGFRB (0.41) | METPDGFRBPDGFRALRRK2 | |
| SCHEMBL371343 | 0.92 | PDGFRB (0.45) | METPDGFRBPDGFRALRRK2 | |
| SCHEMBL14915761 | 0.92 | MET (0.41) | METALDH1A1PDGFRBPDGFRAGRIN2B | |
| SCHEMBL10283523 | 0.91 | MET (0.39) | METPDGFRBPDGFRALRRK2GRIN2B | |
| SCHEMBL10283772 | 0.91 | MET (0.35) | METKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL359863 | 0.90 | PDGFRB (0.34) | METKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL14916383 | 0.90 | MET (0.42) | METKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL14915783 | 0.89 | JAK2 (0.38) | PDGFRBPDGFRALRRK2 | |
| SCHEMBL14916575 | 0.89 | GRIN1 (0.37) | METPDGFRBPDGFRAPPARAGRIN2B | |
| SCHEMBL10283774 | 0.89 | LRRK2 (0.36) | METPDGFRBPDGFRALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | claimed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | claimed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | MET 3/4885KDM4E 429/4885ALDH1A1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.